Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

NCT00538434 is registered in ClinicalTrials.gov with Ception Therapeutics as lead sponsor.

NCT NCT00538434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00538434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
Lead sponsor
Ception Therapeutics
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2008
Completion date
October 31, 2009
Enrollment
227 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic esophagitis